Calcaneal Heel Spur (Symptomatic)
Investigational use for symptomatic plantar calcaneal spur; distinguished from plantar fasciitis by radiographic spur with localized pain.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for symptomatic heel spur. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with one small case series.
- What evidence exists?
- Tier C (investigational). One small case series (n=20) reports 45 percent VAS heel pain reduction at 8 weeks after 2 sessions placed at the medial calcaneal tubercle. There are no controlled trials. Plantar calcaneal spur is a radiographic finding frequently coexisting with plantar fasciitis but distinct clinically — pain is well-localized to the spur point. Evidence-based first-line management is plantar fascia and gastrocnemius stretching, heel-cushioning orthotics, NSAIDs, and (selectively) corticosteroid injection. Spurs themselves rarely require surgical excision.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the heel pad for 5 to 14 days
- Local skin infection or Aeromonas infection (foot is a higher-risk anatomic site)
- Allergic reaction to leech saliva
- Temporary worsening of heel pain after the procedure
- Catastrophic risk if a leech is placed on a diabetic or insensate foot (this is contraindicated)
- Delay of stretching, orthotics, and corticosteroid injection, which are evidence-based
- Failure to identify alternative diagnoses (tarsal tunnel, plantar fascia rupture, calcaneal stress fracture)
- Who should not consider this
- Patients with diabetes and peripheral neuropathy (insensate foot is high-risk)
- Patients within 4 weeks of local corticosteroid injection
- Patients with active foot infection or open wound
- Patients with peripheral vascular disease and reduced ankle-brachial index
- Patients on anticoagulants or with severe anemia
- Patients who have not trialed stretching, heel cushioning, and NSAIDs
- What to ask your clinician
- Has the spur been confirmed radiographically and is it consistent with the location of pain?
- Have I trialed at least 12 weeks of plantar fascia and gastrocnemius stretching?
- Am I using a heel-cushioning orthotic?
- Have alternative diagnoses (tarsal tunnel, stress fracture) been excluded?
- Where exactly will the leech be placed, and what is the foot-care plan?
- What is the realistic expected benefit, given one small case series?
- When to seek urgent care
- Sudden severe heel pain after a snap or pop (rule out plantar fascia rupture)
- New ulceration or non-healing wound on the foot
- Spreading redness, warmth, pus, or red streaks at any bite site or on the foot
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Numbness or tingling in the toes after the procedure
What this does NOT mean
- It does not remove or change the bony spur itself.
- It does not substitute for plantar fascia stretching and heel cushioning, which are first-line.
- It is not appropriate on a diabetic or insensate foot.
- Only one small case series exists; benefit is uncertain beyond placebo or concurrent therapy.
Safety cross-references
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M77.30, M77.31, M77.32
- Safety tier
- low
Evidence Summary
A plantar calcaneal spur is a radiographic finding that frequently coexists with plantar fasciitis but is clinically distinct, with pain well-localized to the spur point. No controlled clinical trial or case series of leech therapy for calcaneal heel spur has been published; use is investigational and mechanistic only, with a rationale presumed to overlap with plantar fasciitis (local anti-inflammatory effects). First-line management remains stretching, orthotics, and selective corticosteroid injection; spurs do not require excision unless very large.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Yıldız S et al. (2018), n=20
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Recent local corticosteroid injection (<4 weeks)
- Diabetic foot or peripheral neuropathy
- Active foot infection
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.